Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

579.95 -1.75 (-0.30%)

Streaming Delayed Price Updated: 11:26 AM EDT, Apr 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

3 Market-Beating Stocks for Long-Term Investors

April 07, 2026

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...

Via StockStory

Topics Energy

United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF

March 31, 2026

In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso...

Via MarketMinute

Chips Down, Ackman Up: How Iran, the Fed, and a Viral Post Defined Monday's Market ↗

March 31, 2026

Via Chartmill

Topics Economy

Why United Therapeutics (UTHR) Stock Is Up Today

March 30, 2026

What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 12.7% in the afternoon session after the company announced its TETON-...

Via StockStory

United Therapeutics Corp. (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗

March 28, 2026

Via Chartmill

United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗

March 04, 2026

Via Chartmill

United Therapeutics Corp. (NASDAQ:UTHR) Reports Record Annual Revenue Despite Q4 Top-Line Miss ↗

February 25, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Monday's session. ↗

March 30, 2026

Via Chartmill

United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

March 30, 2026

From United Therapeutics Corporation

Via Business Wire

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

March 30, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

Via StockStory

Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers

March 23, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

2 Mid-Cap Stocks for Long-Term Investors and 1 We Avoid

March 19, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 That Underwhelm

March 18, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

Topics Firearms

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗

March 16, 2026

Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.

Via The Motley Fool

Topics Regulatory Compliance

This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗

March 16, 2026

Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

March 11, 2026

From United Therapeutics Corporation

Via Business Wire

Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

March 09, 2026

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...

Via StockStory

Topics Artificial Intelligence

United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program

March 09, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference

March 03, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

March 02, 2026

From United Therapeutics Corporation

Via Business Wire

2 Cash-Producing Stocks to Keep an Eye On and 1 That Underwhelm

February 26, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Why United Therapeutics (UTHR) Shares Are Sliding Today

February 26, 2026

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 7.2% in the afternoon session after the company reported fourth-quarter financial results that missed revenue expectations,...

Via StockStory

Topics Earnings

The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough

February 26, 2026

United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company...

Via Finterra

Topics Earnings Economy Intellectual Property

United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’

February 26, 2026

As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ ↗

February 25, 2026

United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.”

Via Stocktwits

United Therapeutics (NASDAQ:UTHR) Misses Q4 CY2025 Revenue Estimates

February 25, 2026

Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 7.4% year on year to $790.2 million. Its GAAP profit of $7.70 per share...

Via StockStory

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

February 25, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics (UTHR) Q4 Earnings Report Preview: What To Look For

February 23, 2026

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings this Wednesday before the bell. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference

February 23, 2026

From United Therapeutics Corporation

Via Business Wire

6 Stock Ideas for the Next 5 Years ↗

February 17, 2026

Listen in as Motley Fool co-founder Tom Gardner and Chief Investment Officer Andy Cross talk about stocks!

Via The Motley Fool

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.